Shots:
- NeuExcell is eligible to receive $190M up front, license fees, R&D, and sales milestones along with royalties
- Spark gets the option to license the global exclusive rights of NeuExcell’s HD program & will receive access to NeuExcell’s neuro-regenerative gene therapy platform & capabilities. NeuExcell is developing AAVs based neuroregenerative gene therapy to regenerate functional new neurons at the site of the neurodegeneration
- The focus of the collaboration is to develop a safe and effective treatment for patients with HD by using NeuExcell’s neuroregenerative gene therapy platform
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post NeuExcell Signs a Research Agreement with Spark to Develop a Novel Gene Therapy for Huntington’s Disease first appeared on PharmaShots.
